Compare CSX Corporation (CSX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Sanofi SA — how do they compare? CSX Corporation trades at $47.6 (market cap $87.70B), while Sanofi SA trades at $40.1 (market cap $95.18B). The key difference: CSX Corporation and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Sanofi SA for 94 Days on average.
| CSX | SNY | |
|---|---|---|
Market Cap | $87.70B | $95.18B |
Volume | 6,980,781 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $53.21 | $52.34 |
52-Week Low | $33.68 | $39.51 |
Typical Hold Time | 55 Days | 94 Days |
Enterprise Value | $105.66B | $114.48B |
Dividend Yield | 1.18% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $46.81, down 1.45% today, with a bearish technical signal from moving averages. The company reported mixed quarterly EPS results, missing in Q4 2025 but beating in Q1 and Q2 2026. Revenue has declined from $14.9B in 2022 to $14.1B in 2025, though 2026 projections show a rebound to $14.5B. Analyst consensus is bullish with a $51 price target, supported by strong institutional buying activity reported in recent SEC filings.
The outlook for CSX hinges on earnings recovery and operational efficiency gains. Key opportunities include pricing power in freight rail and dividend growth, while risks involve revenue volatility and high debt levels. The stock offers potential upside to the consensus target but faces headwinds from economic cycles affecting freight demand.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
